- Home
- LAKE vs DMAC Comparison
LAKE vs DMAC Comparison
Compare LAKE & DMAC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LAKE
- DMAC
- Stock Information
- Founded
- LAKE 1982
- DMAC 2000
- Country
- LAKE United States
- DMAC United States
- Employees
- LAKE N/A
- DMAC N/A
- Industry
- LAKE Industrial Specialties
- DMAC Biotechnology: Pharmaceutical Preparations
- Sector
- LAKE Health Care
- DMAC Health Care
- Exchange
- LAKE Nasdaq
- DMAC Nasdaq
- Market Cap
- LAKE 192.4M
- DMAC 178.0M
- IPO Year
- LAKE 1986
- DMAC N/A
- Fundamental
- Price
- LAKE $18.29
- DMAC $4.23
- Analyst Decision
- LAKE Strong Buy
- DMAC Strong Buy
- Analyst Count
- LAKE 3
- DMAC 2
- Target Price
- LAKE $26.00
- DMAC $8.00
- AVG Volume (30 Days)
- LAKE 75.3K
- DMAC 111.9K
- Earning Date
- LAKE 06-09-2025
- DMAC 05-13-2025
- Dividend Yield
- LAKE 0.66%
- DMAC N/A
- EPS Growth
- LAKE N/A
- DMAC N/A
- EPS
- LAKE N/A
- DMAC N/A
- Revenue
- LAKE $167,211,000.00
- DMAC N/A
- Revenue This Year
- LAKE $28.77
- DMAC N/A
- Revenue Next Year
- LAKE $6.73
- DMAC N/A
- P/E Ratio
- LAKE N/A
- DMAC N/A
- Revenue Growth
- LAKE 34.10
- DMAC N/A
- 52 Week Low
- LAKE $14.58
- DMAC $2.14
- 52 Week High
- LAKE $27.28
- DMAC $6.82
- Technical
- Relative Strength Index (RSI)
- LAKE 51.46
- DMAC 59.70
- Support Level
- LAKE $17.80
- DMAC $4.05
- Resistance Level
- LAKE $19.74
- DMAC $4.33
- Average True Range (ATR)
- LAKE 0.87
- DMAC 0.27
- MACD
- LAKE -0.03
- DMAC 0.03
- Stochastic Oscillator
- LAKE 24.81
- DMAC 86.72
About LAKE Lakeland Industries Inc.
Lakeland Industries Inc manufactures and sells safety garments and accessories for the industrial protective clothing market. Its product segments include Disposables, Chemicals, Fire, Gloves, High Visibility, High-Performance Wear, and Wovens. Its customers include integrated oil, chemical/petrochemical, utilities, automobile, steel, glass, construction, smelting, munition plants, janitorial, pharmaceutical, and mortuaries, as well as scientific and medical laboratories. Its geographical segments include the United States, Latin America, Canada, Asia, Mexico, Europe (United Kingdom), and Other Foreign.
About DMAC DiaMedica Therapeutics Inc.
DiaMedica Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is engaged in developing treatment for ischemic diseases with two main clinical programs focused on acute ischemic stroke (AIS) and preeclampsia (PE). Its main product candidate DM199 (rinvecalinase alfa) is a recombinant form of human tissue kallikrein-1, which is a synthetic version of the naturally occurring protease enzyme kallikrein-1 and a rhKLK1 undergoing clinical development studies in both AIS and PE. The other product candidate in the company's pipeline is DM300, its patented recombinant human ulinastatin, a broad-spectrum serine protease inhibitor, being developed as a potential therapy for severe acute pancreatitis.